Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Aniracetam | Coluracetam | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 750-1500 mg/day divided into 2-3 doses | 20-80 mg/day divided into 2-3 doses |
| Timing | With fat-containing meals (fat-soluble compound; bioavailability increases significantly with dietary fat) | Morning and early afternoon. Sublingual administration may provide faster onset. With or without food. |
| Cycle Duration | Cycles of 8-12 weeks on, 4 weeks off | Cycles of 4-8 weeks on, 2-4 weeks off |
| Evidence Level | moderate_human | animal_plus_anecdotal |
Potent positive allosteric modulator of AMPA receptors with 5-10x the potency of piracetam, slowing both channel closing rate and microscopic desensitization rates. Also modulates metabotropic glutamate receptors (mGluRs), activates nicotinic acetylcholine receptors, and indirectly boosts dopaminergic and serotonergic neurotransmission, conferring anxiolytic properties.
750-1500 mg/day divided into 2-3 doses
With fat-containing meals (fat-soluble compound; bioavailability increases significantly with dietary fat)
Cycles of 8-12 weeks on, 4 weeks off
Enhances high-affinity choline uptake (HACU) via a unique mechanism distinct from other racetams — it increases HACU even in damaged cholinergic neurons, suggesting a choline uptake enhancement rather than mere stimulation. This HACU enhancement persists even after the compound has been cleared, indicating a lasting modification of choline transporter activity. Also shows affinity for AMPA receptors.
20-80 mg/day divided into 2-3 doses
Morning and early afternoon. Sublingual administration may provide faster onset. With or without food.
Cycles of 4-8 weeks on, 2-4 weeks off
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →